|
|
|
| Efficacy and safety of Capecitabine maintenance in elderly patients with advanced triple negative breast cancer |
| YU Meijian TAN Jinlong CHEN Zhigang |
| The Second Department of Oncology, Shangrao People′s Hospital, Jiangxi Province, Shangrao 334000, China |
|
|
|
|
Abstract Objective To analyze the efficacy and safety of Capecitabine maintenance in elderly patients with advanced triple negative breast cancer. Methods A total of 100 elderly patients with advanced triple negative breast cancer treated in Shangrao People′s Hospital from July 2016 to July 2019 were selected as the research objects, and were divided into control group (50 cases) and observation group (50 cases) by random number table method. The control group was treated with Docetaxel+Doxorubicin+Cyclophosphamide, the observation group was additionally given Capecitabine maintenance therapy. Treatment effect, progression-free survival, median survival and total incidence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 88.00%, higher than that of the control group 64.00%, the difference was statistically significant (P<0.05). The progression-free survival and median survival in the observation group were (7.26±1.42) and (21.32±2.33) months, respectively, longer than (5.62±1.52) and (16.59±2.31) months in the control group, the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was 4.00%, lower than 18.00% in the control group, the difference was statistically significant (P<0.05). Conclusion Capecitabine maintenance therapy can effectively prolong the survival of patients, improve the treatment effect, significantly improve the prognosis of patients, and high safety, less adverse reactions, worthy of promotion.
|
|
|
|
|
|
| [1] |
刘鸥飞，郭彦伟，张红巧，等.甲磺酸阿帕联合卡培他滨三线治疗晚期三阴性乳腺癌患者临床研究[J].实用中西医结合临床，2021，21（10）：47-48.
|
| [2] |
Garrido-Castro AC，Lin NU，Polyak K.Insights into Molecular Classifications of Triple-Negative Breast Cancer：Improving Patient Selection for Treatment[J].Cancer Discov，2019，9（2）：176-198.
|
| [3] |
汤青，孙立柱.卡培他滨联合卡铂对晚期三阴性乳腺癌患者胃肠道反应及生存状况的影响[J].中西医结合心血管病电子杂志，2020，8（34）：62-63.
|
| [4] |
张辰铭.培美曲塞联合顺铂方案治疗晚期三阴乳腺癌的效果[J].海峡药学，2021，33（2）：166-168.
|
| [5] |
孙俪，尹传红.卡培他滨或吉西他滨联合卡铂治疗晚期三阴性乳腺癌的临床疗效及对Ki-67表达情况的影响[J].癌症进展，2019，17（23）：2777-2780.
|
| [6] |
李巍，李海洲，焦立新，等.含铂方案治疗三阴性晚期乳腺癌的临床疗效[J].中国误诊学杂志，2021，16（1）：43-44.
|
| [7] |
张芳媛，王茜.卡培他滨维持治疗在复发转移三阴性乳腺癌中的应用价值[J].系统医学，2020，5（14）：40-43.
|
| [8] |
赵希.卡培他滨单药维持治疗晚期三阴性乳腺癌的效果和对患者生活质量的影响观察[J].中国社区医师，2021， 37（4）：71-72.
|
| [9] |
李音.卡培他滨对新辅助化疗后未达pCR的三阴性乳腺癌患者的治疗作用[D].郑州：郑州大学，2019.
|
| [10] |
王双月，崔建东，张羽，等.卡培他滨节拍化疗在晚期三阴性乳腺癌维持治疗中的效果观察[J].广西医学，2018， 40（19）：2289-2292.
|
| [11] |
祝寅，陈苏杰，梁靓，等.吉西他滨联合卡培他滨用于晚期三阴性乳腺癌的效果及安全性分析[J].海峡药学，2020， 32（9）：105-106.
|
| [12] |
田美娟，王丽，张佳，等.口服小剂量环磷酰胺联合卡培他滨维持治疗晚期三阴性乳腺癌的疗效[J].现代肿瘤医学，2019，27（12）：2097-2100.
|
| [13] |
冯白昌.多西他赛联合卡培他滨治疗晚期三阴性乳腺癌的疗效刍议[J].世界复合医学，2020，6（7）：184-186.
|
| [14] |
徐宁，王艳茹.阿帕替尼联合卡培他滨三线治疗晚期三阴性乳腺癌的效果[J].中国当代医药，2021，28（28）：145-147，156.
|
| [15] |
孟洪汭，王潍博.阿帕替尼联合卡培他滨三线治疗晚期三阴性乳腺癌的疗效观察[J].中国医院用药评价与分析，2019，19（6）：670-672，676.
|
| [16] |
雷香菊.复发转移三阴性乳腺癌化疗有效患者给予卡培他滨维持治疗的效果观察[J].实用中西医结合临床，2019，19（10）：37-39.
|
| [17] |
熊伟.卡培他滨联合多西他赛治疗晚期三阴性乳腺癌的效果与安全性[J].临床合理用药杂志，2021，14（5）：114-116.
|
| [18] |
王爱娟，过怿赟，汪志求.阿帕替尼联合卡培他滨三线治疗晚期三阴性乳腺癌的临床观察[J].中国临床药理学与治疗学，2020，25（4）：433-439.
|
| [19] |
瞿凯泉.晚期乳腺癌维持治疗期间卡培他滨的应用效果研究[J].中国继续医学教育，2020，12（31）：142-145.
|
|
|
|
